# A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

> **NCT02019329** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 32 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **OTHER:** Placebo
- **DRUG:** RO5545965
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT02019329
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019329, "A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02019329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*